Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare

Cellecta  

Charles River Discovery

Elsevier 

 NanoString     

 SeraCare 

Silicon Biosystems   

 Streck 

 TriMetis


XIFIN

  View All Sponsors 


Cambridge Healthtech Institute’s Second Annual

Cancer Immunotherapy

Emerging Biology, New Targets, Development Strategies and Clinical Studies

February 20-22, 2017 | Moscone North Convention Center | San Francisco, CA
Part of the 24th International Molecular Medicine Tri-Conference

 

Immuno-oncology research and the subsequent development of immunotherapies continue to rapidly advance the fight against cancer. Indeed, first-generation agents achieving remarkable clinical success have inspired researchers to pursue a variety of new treatment modalities, creating a robust development landscape now centered on combinations strategies. These next-generation agents, in combination with targeted therapies or other immune-modulators such as checkpoint antibodies, are poised to significantly enhance clinical response in a wider range of cancers, and particularly solid tumors.

Due to the remarkable success of the inaugural event, Cambridge Healthtech Institute is proud to host the Second Annual Cancer Immunotherapy meeting, designed to convene an interdisciplinary collection of cancer researchers, drug developers, and technology providers. Join to discuss current challenges and opportunities from discovery biology to clinical studies. Learn about new technologies and engineering enabling immunotherapy discovery, advances in cancer immunotherapy such as NK cell-based approaches, agonist development and combination strategies, as well as clinical findings.

Who should attend: Directors, Managers, Researchers, and Scientists from Pharma, Biotechs, Academia, Government and Healthcare Organizations working in fields such as immuno-oncology and cancer immunotherapy.

Topics will include, but are not limited to:

Immuno-Oncology 
Molecular biology of tumor microenvironments and immune checkpoint pathways
Novel and emerging tumor antigens for targeting
Mechanisms underlying immunosuppression

Immunomonitoring and Predictive Markers
Predictive preclinical models
Technological innovations enabling immunomonitoring and predictive markers
Mechanism of action of immuno-modulatory agents

Cancer Immunotherapy Strategies 
Monoclonal antibodies and next-generation checkpoint inhibitors
Advances in adoptive therapies

  • T-cell-based therapies
    • CAR-T
    • TCR
    • TIL

  • NK-cell-based therapies

Emerging therapeutic strategies 

  • T-regulatory cells, antigen-presenting cells, myeloid suppressor cells

Combination therapies

  • Checkpoint inhibitor combinations
  • Agonist-checkpoint combination studies

Preclinical studies of novel immuno-modulatory agents
Updates on clinical studies

 

If you would like to submit a proposal to give a presentation at this meeting, please click here

The deadline for submission is July 29, 2016.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:

For partnering and sponsorship information, please contact:

Kip Harry
Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5454
E: kharry@healthtech.com

Jon Stroup (Companies A-K)
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com

Joseph Vacca (Companies L-Z) 
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5431
E: jvacca@healthtech.com